UBS sets USD 650.00 target for Chemed stock

Published on 10/20/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemed reports results on October 27, 2026. Chemed stock costs EUR 458.00 on October 20, 2026 at 9:40 p.m. CEST, up 1.43 percent on NYSE.

Analyst target and reporting date

UBS initiated coverage with a Buy rating on September 25, 2026.
Chemed generated USD 673.25 million in second-quarter 2026 revenue and USD 67.70 million in net income.
Chemed stock costs EUR 458.00 at Lang & Schwarz on October 20, 2026 at 9:40 p.m. CEST, up 1.43 percent versus the NYSE prior close of October 19, 2026 at USD 508.29.
Chemed will publish third-quarter 2026 results on October 27, 2026.

CHE, US16359R1032, Illustration mit AI erstellt.

Chemed (ISIN US16359R1032) has a USD 650.00 price target from UBS, which began coverage with a Buy rating on September 25, 2026, according to MarketScreener. The target was 26.08 percent above Chemed's USD 515.57 NYSE price on October 20, 2026. Chemed stock was trading at EUR 458.00 at Lang & Schwarz on October 20, 2026 at 9:40 p.m. CEST, up 1.43 percent against the NYSE prior close of October 19, 2026 at USD 508.29.

Results date sets the next test

Chemed will release its third-quarter results after the NYSE close on October 27, 2026, and will discuss them during a conference call on October 28 at 10:00 a.m. ET. The company announced those dates in an October 1, 2026 release carried on its investor-relations site.

The release covers the quarter ended September 30, 2026. For investors, the coming report will provide the next comparison with Chemed's second-quarter performance, rather than a new annual forecast.

Second-quarter growth supports the setup

Chemed reported USD 673.25 million in second-quarter 2026 revenue and USD 67.70 million in net income, according to MarketBeat. Revenue increased 8.80 percent from the second quarter of 2025, while net income rose 29.00 percent from USD 52.50 million. The net profit margin was 10.06 percent in the second quarter of 2026.

MarketBeat listed analyst expectations of USD 685.04 million in third-quarter revenue and USD 6.39 in earnings per share. Those estimates provide a direct hurdle for the October 27 release, while the company's fiscal 2026 earnings-per-share guidance remains USD 25.00 to USD 25.75.

Valuation against healthcare peers

At the October 20, 2026 NYSE quote, Chemed had a market capitalization of USD 6.7 billion and a price-to-earnings ratio of 25.84. Its 52-week range was USD 365.21 to USD 557.00, placing the current USD 515.57 price 7.44 percent below the high.

Comparison with peers

Chemed (NYSE, USD): up 1.43 percent, P/E 25.84, market capitalization USD 6.7 billion. ResMed (NYSE, USD): up 2.55 percent, P/E 23.59, market capitalization USD 34.6 billion. Henry Schein (Nasdaq, USD): up 0.96 percent, P/E 24.68, market capitalization USD 9.4 billion.

Chemed stock keeps a dated catalyst

The next concrete checkpoint is October 27, 2026, followed by the October 28 conference call. The UBS target and the approaching results date give the stock two separate reference points, while the second-quarter figures set the operating benchmark.

The further course of trading is shown by the continuously updated real-time quote of Chemed stock.